Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)

Assessment Status Rapid Review Complete
Drug Nivolumab plus ipilimumab
Brand Opdivo® plus Yervoy®
Indication For the treatment of advanced melanoma.
Assessment Process
Rapid review commissioned 27/06/2016
Rapid review completed 07/11/2016
Rapid review outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.